JP2022513691A5 - - Google Patents
Info
- Publication number
- JP2022513691A5 JP2022513691A5 JP2021531294A JP2021531294A JP2022513691A5 JP 2022513691 A5 JP2022513691 A5 JP 2022513691A5 JP 2021531294 A JP2021531294 A JP 2021531294A JP 2021531294 A JP2021531294 A JP 2021531294A JP 2022513691 A5 JP2022513691 A5 JP 2022513691A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- dose
- cells
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862774209P | 2018-12-01 | 2018-12-01 | |
| US62/774,209 | 2018-12-01 | ||
| US201962816187P | 2019-03-10 | 2019-03-10 | |
| US62/816,187 | 2019-03-10 | ||
| US201962931487P | 2019-11-06 | 2019-11-06 | |
| US62/931,487 | 2019-11-06 | ||
| PCT/US2019/063282 WO2020112796A1 (en) | 2018-12-01 | 2019-11-26 | Chimeric antigen receptors targeting b-cell maturation antigen and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513691A JP2022513691A (ja) | 2022-02-09 |
| JP2022513691A5 true JP2022513691A5 (https=) | 2022-12-05 |
Family
ID=69063865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531294A Pending JP2022513691A (ja) | 2018-12-01 | 2019-11-26 | Ｂ細胞成熟抗原を標的とするキメラ抗原受容体およびその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20200261503A1 (https=) |
| EP (1) | EP3886989A1 (https=) |
| JP (1) | JP2022513691A (https=) |
| KR (1) | KR20210099574A (https=) |
| CN (1) | CN113498353A (https=) |
| AU (1) | AU2019386063A1 (https=) |
| BR (1) | BR112021010279A2 (https=) |
| CA (1) | CA3116720A1 (https=) |
| CO (1) | CO2021005004A2 (https=) |
| IL (1) | IL283144A (https=) |
| MX (1) | MX2021006395A (https=) |
| PE (1) | PE20211915A1 (https=) |
| PH (1) | PH12021550909A1 (https=) |
| SG (1) | SG11202105353PA (https=) |
| TW (1) | TW202039544A (https=) |
| WO (1) | WO2020112796A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10294304B2 (en) | 2015-04-13 | 2019-05-21 | Pfizer Inc. | Chimeric antigen receptors targeting B-cell maturation antigen |
| JP2024517413A (ja) | 2021-04-16 | 2024-04-22 | セルジーン コーポレーション | 以前に幹細胞移植を受けた患者におけるｔ細胞療法 |
| CN118103407A (zh) * | 2021-08-12 | 2024-05-28 | 上海才致药成生物科技有限公司 | 一种双特异性重组蛋白及其用途 |
| KR20240112994A (ko) | 2021-11-03 | 2024-07-19 | 셀진 코포레이션 | 골수종을 치료하는 데 사용하기 위한 b-세포 성숙 항원에 특이적인 키메라 항원 수용체 |
| KR20240137075A (ko) | 2022-01-28 | 2024-09-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 조성물의 제조 방법 |
| KR20250021397A (ko) * | 2022-02-09 | 2025-02-12 | 하다지트 메디칼 리서치 써비시즈 앤드 디벨롭먼트 리미티드 | 면역 관련 질환을 표적으로 하는 항-bcma car, 조성물 및 이의 방법 |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| US20250295771A1 (en) | 2022-05-11 | 2025-09-25 | Celgene Corporation | Methods and uses related to t cell therapy and production of same |
| EP4532695A1 (en) | 2022-05-25 | 2025-04-09 | Celgene Corporation | Methods of manufacturing t cell therapies |
| US20250345432A1 (en) | 2022-05-25 | 2025-11-13 | Celgene Corporation | Method for predicting response to a t cell therapy |
| WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
| WO2024168192A1 (en) | 2023-02-10 | 2024-08-15 | Celgene Corporation | Assessment of bcma in biological samples |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| EP3131927B8 (en) * | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| BR112017013981A2 (pt) | 2015-01-26 | 2018-01-02 | Cellectis | receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer |
| TWI703159B (zh) * | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| US10294304B2 (en) * | 2015-04-13 | 2019-05-21 | Pfizer Inc. | Chimeric antigen receptors targeting B-cell maturation antigen |
| TWI755547B (zh) * | 2016-01-21 | 2022-02-21 | 美商輝瑞股份有限公司 | 靶向表皮生長因子受體變異體iii之嵌合型抗原受體 |
-
2019
- 2019-11-26 WO PCT/US2019/063282 patent/WO2020112796A1/en not_active Ceased
- 2019-11-26 AU AU2019386063A patent/AU2019386063A1/en active Pending
- 2019-11-26 EP EP19829720.2A patent/EP3886989A1/en active Pending
- 2019-11-26 SG SG11202105353PA patent/SG11202105353PA/en unknown
- 2019-11-26 MX MX2021006395A patent/MX2021006395A/es unknown
- 2019-11-26 US US16/695,894 patent/US20200261503A1/en active Pending
- 2019-11-26 CA CA3116720A patent/CA3116720A1/en active Pending
- 2019-11-26 KR KR1020217017239A patent/KR20210099574A/ko not_active Ceased
- 2019-11-26 PE PE2021000780A patent/PE20211915A1/es unknown
- 2019-11-26 TW TW108142941A patent/TW202039544A/zh unknown
- 2019-11-26 CN CN201980079534.9A patent/CN113498353A/zh active Pending
- 2019-11-26 JP JP2021531294A patent/JP2022513691A/ja active Pending
- 2019-11-26 BR BR112021010279-5A patent/BR112021010279A2/pt unknown
-
2021
- 2021-04-19 CO CONC2021/0005004A patent/CO2021005004A2/es unknown
- 2021-04-22 PH PH12021550909A patent/PH12021550909A1/en unknown
- 2021-05-12 IL IL283144A patent/IL283144A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022513691A5 (https=) | ||
| JP7589200B2 (ja) | 抗アクチビンａ抗体及びその使用 | |
| US10251945B2 (en) | Anti-ICOS agonist antibodies and uses thereof | |
| CN105198997B (zh) | Cd37免疫治疗剂及其与双功能化学治疗剂的联合 | |
| TW202302636A (zh) | 靶向ｂｃｍａ、ｇｐｒｃ５ｄ及ｃｄ３之三特異性抗體 | |
| US20200261503A1 (en) | Chimeric antigen receptors targeting b-cell maturation antigen and methods of use thereof | |
| KR20200037388A (ko) | Nkg2d, cd16, 및 egfr, hla-e, ccr4 또는 pd-l1에 결합하는 단백질 | |
| KR20200051789A (ko) | Nkg2d, cd16, 및 c-유형 렉틴-유사 분자-1 (cll-1)에 결합하는 단백질 | |
| BR112020015662A2 (pt) | Receptores de antígeno quimérico direcionados a cd70 | |
| US20230250176A1 (en) | Ppharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16 | |
| KR20210002499A (ko) | 항-cd38 항체의 피하 투여 | |
| KR20250153855A (ko) | 항-인간 vista 항체 및 이의 용도 | |
| KR20100052545A (ko) | Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물 | |
| CN107074952A (zh) | 结合犬pd‑l1的pd‑l1抗体 | |
| KR20190120783A (ko) | Gd2, nkg2d 및 cd16에 결합하는 단백질 | |
| CA3156096C (en) | Pd1 and vegfr2 dual-binding agents | |
| KR20190120781A (ko) | Cd123, nkg2d 및 cd16에 결합하는 단백질 | |
| JP7480307B2 (ja) | 免疫細胞関与効果を調節するための手段および方法 | |
| JP2018525339A (ja) | リンパ腫又は白血病におけるリンパ球増加症を誘導することにおける使用のためのヒトｃｓｆ−１ｒに対する抗体 | |
| CN116262135A (zh) | 抗cd27抗体组合物及其用途 | |
| IL292430A (en) | Sequential anti-cd19 therapy | |
| CN119431581A (zh) | 抗原结合蛋白 | |
| US20260070980A1 (en) | Method for treating a t-lymphocyte-mediated disease | |
| RU2021115040A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток, и способы их применения | |
| KR20260036556A (ko) | 결합 작제물 |